Drug Trials Snapshots: VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK

Why It Matters

The results give clinicians a potassium‑competitive acid blocker‑based alternative that may improve eradication rates and simplify dosing, potentially shifting H. pylori treatment standards.

Key Takeaways

• VOQUEZNA TRIPLE PAK achieved 84.7% H. pylori eradication in mITT
• VOQUEZNA DUAL PAK matched lansoprazole with 78.5% eradication rate
• Both regimens showed similar safety; diarrhea rates lower than comparator
• No efficacy differences across sex, race, or age subgroups

Pulse Analysis

Helicobacter pylori infection remains a global health challenge, affecting roughly half of the world’s population and contributing to peptic ulcer disease and gastric cancer. Standard eradication regimens rely on proton‑pump inhibitors combined with antibiotics, but rising antimicrobial resistance has eroded their effectiveness. Vonoprazan, a potassium‑competitive acid blocker, offers a more potent and consistent gastric pH elevation, creating a favorable environment for antibiotics to work. Phathom’s VOQUEZNA formulations leverage this mechanism, positioning them as next‑generation options in the crowded H. pylori market.

The pivotal Phase III trial enrolled 992 adults across the United States and several European sites, randomizing participants to VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, or a lansoprazole‑based triple therapy. The triple regimen achieved an 84.7% eradication rate in the mITT cohort, surpassing the 78.8% control, while the dual regimen posted a comparable 78.5% rate. Statistical analysis confirmed non‑inferiority for the dual arm and superiority for both vonoprazan‑based arms in several subpopulations, including patients with resistant bacterial strains. Importantly, efficacy was uniform across sex, race, and age groups, suggesting broad applicability in diverse patient populations.

Safety outcomes reinforced the clinical promise of vonoprazan‑based therapy. Common adverse events such as diarrhea, dysgeusia, and abdominal pain occurred at lower frequencies than in the lansoprazole comparator, and serious allergic reactions remained rare. These findings, combined with a simplified twice‑daily dosing schedule for the triple pack, could drive higher patient adherence and reduce treatment failures. As clinicians seek more reliable eradication strategies, VOQUEZNA’s FDA approval may catalyze a shift toward acid‑blocker‑centric regimens, prompting insurers and formularies to reassess coverage policies and potentially reshaping the therapeutic landscape for H. pylori worldwide.